Clinical trials recruiting for Lung cancer
2,180
Recruiting trials
51
US states with sites
78
Countries
8%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Carboplatin | 114 |
| Pembrolizumab | 97 |
| Pemetrexed | 80 |
| Cisplatin | 56 |
| Paclitaxel | 44 |
| Osimertinib | 41 |
| Atezolizumab | 40 |
| Docetaxel | 39 |
| Durvalumab | 34 |
| Nivolumab | 29 |
| Etoposide | 27 |
| Nab-paclitaxel | 22 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 339 |
| California | 333 |
| New York | 290 |
| Florida | 250 |
| Virginia | 201 |
| Ohio | 195 |
| Massachusetts | 186 |
| Tennessee | 186 |
| Illinois | 178 |
| Pennsylvania | 176 |
| Michigan | 164 |
| New Jersey | 157 |
Top cities
Houston, Texas 246New York, New York 200Boston, Massachusetts 163Nashville, Tennessee 150Los Angeles, California 140Fairfax, Virginia 139Chicago, Illinois 127St Louis, Missouri 100Philadelphia, Pennsylvania 93Seattle, Washington 93
Self-screener
Recruiting trials
- 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 3D Virtual Resection for Predicting Lung Function in VATS
- 4D-MRI for Precision Medicine
- 68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- 68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
- 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A Beta-only IL-2 ImmunoTherapY Study
- A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
- A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
- A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
- A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- A Clinico-biological Database of Lung Cancers
- A Community Health Worker Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers
- A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
- A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
- A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
- A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
- A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
- A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
- A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
- A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
- A Multicenter Cancer Biospecimen Collection Study
- A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).
- A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
- A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
- A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
- A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
- A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
- A National Registry on Chinese Patients With Lymphangioleiomyomatosis
- A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
- A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
- A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
- A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
- A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase 1/1b Study of IAM1363 in HER2 Cancers
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
- A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Related conditions
Trials recruiting for Lung cancer often also study these conditions. Each links to its own recruiting-trial list.
Non-small cell lung cancer 507Breast cancer 2239Colorectal cancer 1359Pancreatic cancer 870Melanoma 487Prostate cancer 1234Small cell lung cancer 87Ovarian cancer 118Gastric cancer 91Cervical cancer 71
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Lung cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.